Re:Search Institution Members

149 Results for Members

Members

The University of Mauritius focuses on capacity building and instilling community responsibility through its...

The Alexandria University is a public research university in Alexandria, Egypt.

Merck KGaA is a pharmaceutical and life sciences company and a funding member of WIPO Re:Search. The company...

Murdoch Children's Research Institute (MCRI) specializes in research to prevent and treat childhood conditions...

The National Center for Genetic Engineering and Biotechnology (BIOTEC) functions as a research institute, with...

The National Institute of Industrial Property (INPI) is the official government body responsible for...

162 Results for Collaborations

Collaborations

PATH and a researcher from McMaster University co-developed a microfluidic diagnostic to detect bacteria in banked milk.

Merck KGaA, Darmstadt, Germany will provide a University of California, San Diego (UCSD) investigator with a targeted library of phosphoinositide-3-kinase (PI3K) inhibitors. The UCSD investigator will screen these inhibitors for activity against the causative agents of Chagas disease, human African trypanosomiasis, and leishmaniasis.

Merck KGaA, Darmstadt, Germany will provide a University of Buea researcher with a subset of highly potent Hsp90 inhibitors to screen against Onchocerca worms, and identify compounds that selectively kill both microfilariae and adult O. volvulus, without adverse effects to Loa loa microfilariae.

MSD provided an Emory University researcher studying tuberculosis with membrane-bound protein purification expertise.

MSD will provide a UCSF/UCSD researcher with HMG-CoA reductase inhibitors (statins) to screen against schistosomal worms. CIDR will attempt to solve the structure of the S. mansoni HMG-CoA reductase.

MSD will provide a WEHI researcher with a targeted set of compounds to screen against Plasmodium.

170 Results for Assets

Assets

Fenarimol as starting point for SAR investigations aimed at improving activity against T.cruzi and developing compounds suitable for in vivo characterisation. This second release of data contains data sets on the two more advanced fenarimol series, from which two preclinical candidates were identified.
A novel axenic amastigote Leishmania assay was developed and validated that reports only cytocidal molecules. It was used to screen a diversity-oriented synthesis library and two new chemical series with antileishmanial activity were identified. The new axenic assay has a significantly improved translation to the intracellular assay.
The University of Bamako is willing to enter into partnerships with organizations looking to make use of its five sites for clinical trials, which are certified by the Clinical and Laboratory Standards Institute. Its facilities are also certified for hematology and biochemistry, and specialize in malaria drugs and vaccines. The university also has experience with other parasitic diseases including schistosomiasis, onchocerciasis and leishmaniasis. The university can also provide staff for volunteer recruitment, monitoring, clinical care for volunteers, and the possibility for interaction with the community.
A low cost production process for mefloquine hydrochloride has been developped (new method of synthesis). This could significantly reduce the production cost of a combination product such as ASMQ.
Screening commercially available compounds in GNF's nonproprietary libraries identified inhibitors of proliferation of P. falciparum strain 3D7 in human erythrocytes. The dataset contains the structures and screening data for over 5,600 compounds, which were tested in dose response and confirmed to inhibit parasite growth by more than 50% at the highest screening concentration (1.25 or 12.5 uM). Over 3200 compounds of these compounds were available for testing in powder format which allowed for testing at higher concentrations (12.5 uM) using freshly diluted stocks. Activity against the multidrug resistant W2 strain is also available. In addition, we have included data for a human cell cytotoxicity selectivity screen using the Huh7 human hepatocellular carcinoma cell line and deposited an indication of the 'promiscuity' of the hits (the IFI index) in other high-throughput assays at the Genomics Institute of the Novartis Research Foundation. All efforts have been made to ensure data quality and accuracy, but users are reminded that these data carry the usual caveats associated with results from large scale screening.